{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T20:29:23Z","timestamp":1744921763931,"version":"3.37.3"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ymthe.2020.02.011","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T05:46:59Z","timestamp":1582177619000},"page":"706-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["CRISPR-Cas9 Disruption of Aquaporin 1: An Alternative to Glaucoma Eye Drop Therapy?"],"prefix":"10.1016","volume":"28","author":[{"given":"Andr\u00e1s M.","family":"Kom\u00e1romy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.02.011_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.02.011_bib2","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990-2020: a systematic review\u00a0and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ymthe.2020.02.011_bib3","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2020.02.011_bib4","doi-asserted-by":"crossref","first-page":"16067","DOI":"10.1038\/nrdp.2016.67","article-title":"Primary open-angle glaucoma","volume":"2","author":"Weinreb","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2020.02.011_bib5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ymthe.2019.12.012","article-title":"Gene therapy for glaucoma by ciliary body aquaporin 1 disruption using CRISPR-Cas9","volume":"28","author":"Wu","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.02.011_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11095-018-2557-4","article-title":"Glaucoma - next generation therapeutics: impossible to possible","volume":"36","author":"Adams","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2020.02.011_bib7","article-title":"Cost-utility analysis of glaucoma medication adherence","author":"Newman-Casey","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.02.011_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/jop.2017.0024","article-title":"Aquaporins: novel targets for age-related ocular disorders","volume":"34","author":"Patil","year":"2018","journal-title":"J.\u00a0Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2020.02.011_bib9","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2020.02.011_bib10","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1172\/JCI120429","article-title":"Gene therapy and genome surgery in the retina","volume":"128","author":"DiCarlo","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.02.011_bib11","article-title":"Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives","author":"Garafalo","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2020.02.011_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/02713688809047029","article-title":"Cell turnover in ciliary epithelium compared to other slow renewing epithelia in the adult mouse","volume":"7","author":"McDonald","year":"1988","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ymthe.2020.02.011_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/hum.2019.144","article-title":"Ocular inflammatory response to intravitreal injection of adeno-associated virus vector: relative contribution of genome and capsid","volume":"31","author":"Timmers","year":"2020","journal-title":"Hum. Gene Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620300976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620300976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T16:11:55Z","timestamp":1727712715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620300976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1525001620300976"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.02.011","relation":{},"ISSN":["1525-0016"],"issn-type":[{"type":"print","value":"1525-0016"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR-Cas9 Disruption of Aquaporin 1: An Alternative to Glaucoma Eye Drop Therapy?","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.12.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}